455 Stock Overview
Engages in the research and development, manufacture, and sale of pharmaceutical, biotechnology, and healthcare products in Mainland China, Hong Kong, and Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Tianda Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.19 |
| 52 Week High | HK$0.28 |
| 52 Week Low | HK$0.16 |
| Beta | 0.095 |
| 1 Month Change | 9.30% |
| 3 Month Change | 1.62% |
| 1 Year Change | 2.73% |
| 3 Year Change | -16.44% |
| 5 Year Change | -6.00% |
| Change since IPO | -67.86% |
Recent News & Updates
Is Tianda Pharmaceuticals (HKG:455) Weighed On By Its Debt Load?
Dec 10
Lacklustre Performance Is Driving Tianda Pharmaceuticals Limited's (HKG:455) 25% Price Drop
Oct 28Recent updates
Is Tianda Pharmaceuticals (HKG:455) Weighed On By Its Debt Load?
Dec 10Lacklustre Performance Is Driving Tianda Pharmaceuticals Limited's (HKG:455) 25% Price Drop
Oct 28Tianda Pharmaceuticals Limited (HKG:455) Investors Are Less Pessimistic Than Expected
Aug 16Is Tianda Pharmaceuticals (HKG:455) Using Debt In A Risky Way?
Jun 20There's Reason For Concern Over Tianda Pharmaceuticals Limited's (HKG:455) Massive 26% Price Jump
Mar 27Estimating The Fair Value Of Tianda Pharmaceuticals Limited (HKG:455)
Mar 02Is Tianda Pharmaceuticals (HKG:455) Using Debt Sensibly?
May 23Tianda Pharmaceuticals (HKG:455) Has Debt But No Earnings; Should You Worry?
Dec 06Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?
Jan 11Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?
Aug 05Is Tianda Pharmaceuticals (HKG:455) Using Too Much Debt?
Dec 11Shareholder Returns
| 455 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | -4.1% | 0.8% | 0.4% |
| 1Y | 2.7% | 6.7% | 24.4% |
Return vs Industry: 455 underperformed the Hong Kong Pharmaceuticals industry which returned 6.7% over the past year.
Return vs Market: 455 underperformed the Hong Kong Market which returned 24.4% over the past year.
Price Volatility
| 455 volatility | |
|---|---|
| 455 Average Weekly Movement | 9.3% |
| Pharmaceuticals Industry Average Movement | 4.9% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in HK Market | 13.9% |
| 10% least volatile stocks in HK Market | 3.0% |
Stable Share Price: 455 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 455's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 695 | Alan Fang | www.tiandapharma.com |
Tianda Pharmaceuticals Limited, together with its subsidiaries, engages in the research and development, manufacture, and sale of pharmaceutical, biotechnology, and healthcare products in Mainland China, Hong Kong, and Australia. It provides Chinese medicines, chemical drugs, biological and health products, and medical appliances covering therapy areas of cardio-cerebrovascular, pediatric, anti-flu and respiratory, anti-infection, detoxification, anti-cancer, and others. The company offers its health products under the Herb Valley and Tuokang brands.
Tianda Pharmaceuticals Limited Fundamentals Summary
| 455 fundamental statistics | |
|---|---|
| Market cap | HK$404.21m |
| Earnings (TTM) | -HK$47.26m |
| Revenue (TTM) | HK$384.68m |
1.1x
P/S Ratio-8.6x
P/E RatioIs 455 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 455 income statement (TTM) | |
|---|---|
| Revenue | HK$384.68m |
| Cost of Revenue | HK$208.40m |
| Gross Profit | HK$176.28m |
| Other Expenses | HK$223.54m |
| Earnings | -HK$47.26m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.022 |
| Gross Margin | 45.83% |
| Net Profit Margin | -12.29% |
| Debt/Equity Ratio | 16.9% |
How did 455 perform over the long term?
See historical performance and comparisonDividends
1.4%
Current Dividend Yield-12%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/02 03:01 |
| End of Day Share Price | 2025/01/28 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Tianda Pharmaceuticals Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jayaprabha Dhavale | Virtua Research Inc. |